A 52-week Randomised, Double-blind, Parallel Group, Safety and Efficacy Study of Empagliflozin Once Daily as add-on Therapy to Glucagon-like Peptide-1 Receptor Agonist in Japanese Type 2 Diabetes Mellitus Patients With Insufficient Glycaemic Control
收藏DataCite Commons2025-06-01 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/PR00009757/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
This is a multi-center, randomised, double-blind, parallel-group, safety and efficacy study
of empagliflozin as add-on to GLP-1 RA in Japanese patients with Type 2 Diabetes Mellitus
with insufficient glycaemic control
提供机构：
Vivli
创建时间：
2024-01-12
